List of Excipients in Branded Drug SCOPOLAMINE TRANSDERMAL SYSTEM

« Back to Dashboard

Generic Drugs Containing SCOPOLAMINE TRANSDERMAL SYSTEM

Company	Ingredient	NDC	Excipient
Padagis Israel Pharmaceuticals Ltd	scopolamine transdermal system	45802-580	CROSPOVIDONE
Padagis Israel Pharmaceuticals Ltd	scopolamine transdermal system	45802-580	ISOPROPYL PALMITATE
Padagis Israel Pharmaceuticals Ltd	scopolamine transdermal system	45802-580	LIGHT MINERAL OIL
Padagis Israel Pharmaceuticals Ltd	scopolamine transdermal system	45802-580	POLYISOBUTYLENE
Bryant Ranch Prepack	scopolamine transdermal system	71335-2718	CROSPOVIDONE
Bryant Ranch Prepack	scopolamine transdermal system	71335-2718	ISOPROPYL PALMITATE

What are the Most Frequently-Used Excipients in SCOPOLAMINE TRANSDERMAL SYSTEM?

# Of NDCs	Excipient
2	CROSPOVIDONE
2	ISOPROPYL PALMITATE
2	LIGHT MINERAL OIL
2	POLYISOBUTYLENE

Scopolamine Transdermal System Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: October 19, 2026

Scopolamine transdermal systems have a relatively simple active ingredient profile but demanding performance requirements. The reference product, Transderm Scop, delivers 1.5 mg of scopolamine over up to 72 hours, with approximately 0.5 mg reaching systemic circulation. The commercial opportunity is strongest in generic substitution, lower-cost patch manufacturing, improved adhesion, and differentiated delivery systems rather than in new chemical-entity exclusivity.

The reference patch uses scopolamine base with a pressure-sensitive adhesive system that includes light mineral oil and polyisobutylene. A competing product must control drug flux, residual drug content, adhesion, release-liner performance, skin irritation, and dose delivery over three days. Because scopolamine is a small-molecule drug with an established FDA route of administration, biosimilar risk is not applicable. The principal regulatory pathway is an ANDA for a therapeutically equivalent transdermal system or a 505(b)(2) application for a materially different formulation or delivery technology.

What is the FDA-approved scopolamine transdermal system?

Transderm Scop is an extended-release transdermal patch indicated for prevention of nausea and vomiting associated with motion sickness and recovery from anesthesia or surgery. The patch is applied behind the ear at least four hours before exposure to the relevant trigger and is intended to remain in place for up to three days [1].

Attribute	Reference product profile
Active ingredient	Scopolamine
Dosage form	Transdermal system
Nominal drug content	1.5 mg per patch
Approximate systemic delivery	0.5 mg over up to 72 hours
Application site	Hairless skin behind the ear
FDA application	NDA 017874
Primary use	Motion-sickness and postoperative nausea and vomiting
Product type	Small-molecule prescription transdermal system
Biosimilar pathway	Not applicable

Scopolamine is a centrally acting muscarinic antagonist. Its pharmacology creates a narrow formulation balance: insufficient delivery can reduce efficacy, while excessive systemic exposure can increase anticholinergic effects such as dry mouth, blurred vision, drowsiness, confusion, urinary retention, and disorientation [1].

What excipients are used in the Transderm Scop patch?

The marketed system uses excipients that function primarily as adhesive, vehicle, and structural components. The FDA labeling identifies light mineral oil and polyisobutylene among the inactive ingredients. The complete system also includes a polyester backing and a siliconized polyester release liner [1].

Excipient functions

Component	Likely functional role	Commercial significance
Scopolamine base	Active pharmaceutical ingredient	Must remain chemically stable and sufficiently soluble in the adhesive matrix
Light mineral oil	Plasticizer and vehicle	Influences drug mobility, adhesive rheology, and skin contact
Polyisobutylene	Pressure-sensitive adhesive	Controls tack, cohesion, cold flow, and drug diffusion
Polyester backing	Occlusive structural layer	Controls mechanical integrity and limits outward drug loss
Siliconized polyester liner	Protective release layer	Controls liner removal and patch handling

Polyisobutylene is commercially attractive because it is well established in pressure-sensitive adhesive systems and can provide long wear with relatively low volatility. Its limitations include potential cold flow, changes in tack under heat, and the need to control molecular-weight distribution and polymer grade.

Light mineral oil can improve adhesive flexibility and drug mobility. Excessive plasticization may reduce cohesion, increase edge lift, alter scopolamine diffusion, or change residual drug content. A generic manufacturer therefore cannot treat the excipient system as interchangeable based only on nominal composition. Polymer grade, oil-to-polymer ratio, mixing history, coating thickness, drying conditions, and liner contact can all affect release.

How should an excipient strategy be designed for a scopolamine patch?

The preferred strategy is to preserve the reference product's functional performance while minimizing formulation complexity. A generic developer should prioritize a solvent-free or low-solvent adhesive matrix with robust control over drug loading and continuous delivery.

Drug solubility and crystallization control

Scopolamine base must remain molecularly dispersed in the adhesive phase throughout shelf life. Crystallization can reduce the effective thermodynamic activity of the drug and create inconsistent flux. It can also generate visible particles, change adhesive properties, and complicate content-uniformity testing.

Critical development variables include:

• Scopolamine base particle size and solid-state form.
• Drug-to-polymer ratio.
• Mineral-oil concentration.
• Moisture exposure.
• Coating and drying temperature.
• Storage temperature and humidity.
• Compatibility between the drug, adhesive, backing, and liner.

A formulation that achieves the target release profile immediately after manufacture but crystallizes during accelerated aging is commercially unsuitable.

Adhesion and wear performance

The patch must remain attached for up to 72 hours despite perspiration, bathing, skin movement, and contact with hair or skin oils. The adhesive should have sufficient initial tack for placement behind the ear but should not leave excessive residue or cause traumatic removal.

Performance testing should measure:

• Initial tack.
• Peel adhesion.
• Shear resistance.
• Edge lift after wet exposure.
• Adhesion after 24, 48, and 72 hours.
• Residual adhesive on skin.
• Removal force.
• Skin irritation and sensitization.

A higher-tack adhesive is not automatically superior. Excessive adhesion can increase skin irritation and complicate removal, while excessive plasticizer can impair cohesive strength.

Permeation control

Scopolamine is sufficiently potent that a small change in flux can materially affect exposure. The backing layer, adhesive matrix, drug activity, and skin-contact area jointly determine delivery.

A robust development program should compare:

1. In vitro release from the patch.
2. In vitro permeation through human or validated surrogate skin.
3. Adhesion under use conditions.
4. Pharmacokinetic exposure in an adequately designed bioequivalence study.
5. Residual drug remaining in the system after wear.

The residual drug question has commercial and safety importance. A patch can deliver the correct average dose while retaining a large amount of active ingredient at disposal. Packaging and patient instructions should address used-patch handling, especially because scopolamine can cause toxicity through unintended contact or ingestion.

What formulations are protected by the reference product?

The reference technology is a multilayer transdermal system based on scopolamine incorporated into an adhesive delivery structure. Protection historically associated with this product would be expected to focus on combinations of:

• Scopolamine in a transdermal reservoir or matrix.
• A pressure-sensitive adhesive composition.
• A backing layer and release liner.
• Controlled delivery over approximately three days.
• Placement behind the ear.
• Specific adhesive or polymer compositions.
• Manufacturing methods for coating, drying, laminating, and converting the patch.

The commercially relevant distinction is between the marketed product's formulation and the broader technical concept of transdermal scopolamine delivery. A formulation can avoid a narrow composition claim while still requiring substantial comparative data for FDA approval.

What is the patent and exclusivity position for scopolamine transdermal systems?

The principal commercial protection for Transderm Scop is no longer expected to come from new-chemical-entity exclusivity. Scopolamine and the transdermal product have been marketed for decades. The key barriers are therefore regulatory approval, bioequivalence, manufacturing capability, trademarks, and any surviving formulation or method-of-use claims.

Exclusivity category	Current commercial relevance
New chemical entity exclusivity	Expired
Original product patent protection	Historically important but largely aged out
Pediatric exclusivity	Not a principal current barrier based on the product's age
Orphan exclusivity	Not applicable to the principal indications
Biosimilar exclusivity	Not applicable
FDA-approved generic pathway	Potentially available through ANDA, subject to Orange Book and regulatory requirements
Formulation patents	Must be checked in current USPTO and FDA records before launch
Method-of-use patents	Must be checked for listed, unexpired claims and indication scope

The FDA Orange Book is the controlling source for patents listed against an approved NDA. Patent status should be verified against the current Orange Book entry for NDA 017874 rather than inferred from historical patent searches [2]. Patent expiration should also be checked in the USPTO Patent Center and relevant national registers because continuation, terminal-disclaimer, reexamination, and patent-term-adjustment records can change the analysis [3].

When does scopolamine transdermal exclusivity expire?

The historic regulatory exclusivity periods for scopolamine transdermal delivery have expired or are not commercially determinative. No current biosimilar exclusivity period applies because the product is not a biologic.

The relevant launch question is whether a generic applicant must make a Paragraph IV certification against any unexpired Orange Book-listed patent. If no blocking listed patent remains, an ANDA applicant could seek approval without waiting for patent expiration, subject to FDA review and any applicable exclusivity or regulatory delay.

How do Paragraph IV challenges apply?

An ANDA applicant would typically certify under Paragraph IV that any listed patent is invalid, unenforceable, or will not be infringed by the proposed product. A Paragraph IV notice can trigger patent litigation under the Hatch-Waxman Act. A lawsuit filed within the statutory period can impose a 30-month stay on FDA approval, subject to statutory exceptions and court decisions [4].

For an old transdermal product, the highest litigation risk would usually come from a surviving formulation, adhesive, manufacturing, or delivery patent rather than from the original composition-of-matter patent.

What is the Orange Book status of Transderm Scop?

The relevant FDA record is NDA 017874 for Transderm Scop. Orange Book review should cover:

• Current patent listings.
• Patent-use codes.
• Reference listed drug status.
• Approved dosage form and route.
• Any exclusivity codes.
• Withdrawal or discontinuation status.
• Therapeutic-equivalence evaluations for approved generics.

FDA Orange Book records can change as patents expire, listings are withdrawn, or administrative corrections are made. A commercial diligence report should use the current FDA electronic Orange Book record and preserve a dated copy of the search results [2].

Which companies are challenging the scopolamine transdermal market?

The competitive field is limited compared with oral antiemetics and newer postoperative nausea products. Competition can come from four categories:

Competitor category	Examples or strategy	Risk to a new patch
Generic transdermal systems	ANDA products equivalent to Transderm Scop	Direct price competition
Oral antiemetics	Meclizine, dimenhydrinate, ondansetron	Lower manufacturing barriers
Injectable antiemetics	Ondansetron and other perioperative products	Institutional substitution
Improved delivery systems	Matrix patches, microneedles, longer-wear systems	Differentiation and premium pricing

A generic patch would compete mainly on reimbursement, supply reliability, pharmacy-channel access, and product quality. A differentiated product would need a clinically meaningful advantage, such as improved adhesion, lower skin irritation, reduced residual drug, easier application, or more predictable delivery.

What commercial opportunities exist for excipient suppliers and manufacturers?

Generic substitution

The largest near-term opportunity is a therapeutically equivalent generic transdermal system. The formulation should use widely available excipients and standard coating and laminating equipment. Manufacturers with experience in pressure-sensitive adhesive patches have an advantage over companies that must build the capability from scratch.

Adhesive improvement

An adhesive platform that reduces edge lift, residue, or dermatitis could support a 505(b)(2) product or a lifecycle-management strategy. Acrylics, silicone adhesives, and alternative polyisobutylenes may provide different balances of tack, permeability, and skin tolerance. A change in adhesive, however, can alter exposure and may require extensive comparative data.

Longer wear and lower disposal burden

A patch delivering for four to seven days could offer convenience but would face a higher technical burden. The developer would need to demonstrate controlled delivery, stable adhesion, acceptable residual drug, and no clinically relevant increase in anticholinergic exposure.

Pediatric and geriatric usability

The reference product has age-related safety limitations because scopolamine can produce confusion, hallucinations, sedation, and urinary retention. A commercial product designed for easier application, clearer removal instructions, or a lower-dose configuration could target specific populations, but such positioning would require FDA-supported labeling and clinical evidence.

Manufacturing and process IP

Manufacturing barriers may provide stronger practical protection than excipient composition claims. Relevant process capabilities include:

• Uniform coating of a low-dose, potent active.
• Control of coat weight across large rolls.
• Low-defect lamination.
• Release-liner removal without adhesive transfer.
• Slitting and die-cutting without edge deformation.
• Packaging that limits moisture and drug loss.
• In-process testing for drug content and coat uniformity.

Process patents can be useful if they cover a reproducible coating, drying, or converting method that improves product quality. Trade secrets may be more durable than narrow formulation claims if competitors cannot readily identify process parameters from the finished patch.

What patent litigation affects scopolamine transdermal systems?

The main litigation exposure is a potential Hatch-Waxman case involving an ANDA applicant and the NDA holder or patent owner. The relevant triggers are:

1. An ANDA submission with a Paragraph IV certification.
2. Statutory notice to the patent owner and NDA holder.
3. A patent-infringement complaint.
4. A possible 30-month FDA approval stay.
5. Settlement, judgment, dismissal, or approval after the stay.

No biosimilar litigation framework applies. There is also no basis to assume that a historical lawsuit remains commercially relevant without checking the docket, patent status, and current Orange Book listing.

How strong is the scopolamine transdermal patent estate?

The patent estate appears structurally weaker than that of a recently launched specialty drug because the active ingredient and product have a long market history. Its practical strength depends on whether any unexpired claims cover the specific adhesive matrix, multilayer construction, manufacturing process, or approved use.

Estate component	Relative assessment
Active ingredient	Weak as a current barrier because scopolamine is old
Core transdermal concept	Likely aged and vulnerable to prior art
Adhesive composition	Potentially relevant if claims remain unexpired
Manufacturing process	Potentially stronger as a trade-secret or process barrier
Method of use	Limited unless claims remain listed and indication-specific
Trademark	Commercially relevant but separate from patent exclusivity
Regulatory data	Limited value compared with newly approved products

A formal freedom-to-operate opinion must evaluate claim scope, prosecution history, terminal disclaimers, family members, and jurisdiction-specific status. Patent landscape conclusions should not rely solely on title or abstract matches.

What generic launch scenarios exist?

Scenario 1: Approval without active listed-patent litigation

This is the fastest pathway if the current Orange Book contains no blocking unexpired patents. Commercial entry would still depend on FDA approval, manufacturing scale-up, supply contracts, and pharmacy substitution.

Scenario 2: Paragraph IV challenge and settlement

A generic applicant may challenge a listed patent and settle for a licensed entry date. Settlement economics would depend on the patent's remaining term, the strength of the infringement case, the number of potential entrants, and the expected generic price.

Scenario 3: 505(b)(2) differentiated product

A company could pursue a new patch with different excipients, improved wear, altered dose delivery, or a new indication. This approach may support product differentiation but would require a stronger clinical and regulatory package than an ANDA.

Scenario 4: Non-patch substitution

Oral and injectable antiemetics can limit pricing power even if the transdermal product has no active patent barrier. Hospital formularies and perioperative protocols may favor low-cost alternatives.

How does scopolamine compare with newer transdermal drug products?

Scopolamine has an older, simpler delivery system and a relatively narrow therapeutic application. Newer transdermal products may have stronger protection from polymer technology, device integration, digital adherence features, or formulation patents. Scopolamine's advantage is established clinical use and a known regulatory pathway. Its disadvantage is limited exclusivity and competition from inexpensive oral products.

What is the revenue exposure for a scopolamine patch launch?

Public company reporting generally does not separate Transderm Scop revenue from broader product portfolios. A reliable revenue estimate therefore requires company-specific segment disclosure, prescription data, payer data, and channel assumptions. The key commercial variables are:

• U.S. prescription volume.
• Generic penetration.
• Average selling price.
• Pharmacy versus hospital mix.
• Patch supply reliability.
• Reimbursement tier.
• Number of approved generic competitors.
• Manufacturing yield and scrap rate.

The product's revenue opportunity is more likely to support a focused specialty or generic portfolio strategy than a large platform valuation based solely on the molecule.

Key Takeaways

• Transderm Scop delivers approximately 0.5 mg of scopolamine over up to 72 hours from a 1.5 mg patch.
• The principal excipients are light mineral oil and polyisobutylene, supported by polyester backing and a siliconized polyester release liner.
• The central formulation risks are drug crystallization, variable skin flux, adhesion failure, irritation, and residual drug after use.
• Scopolamine is a small molecule, so biosimilar risk and biologic exclusivity do not apply.
• The original chemical and regulatory exclusivity periods are no longer the main commercial barrier.
• A generic developer should examine the current Orange Book entry for NDA 017874 and conduct a live USPTO patent review before filing.
• The strongest commercial opportunities are generic substitution, adhesive improvement, lower-irritation systems, longer wear, and manufacturing-cost reduction.
• Manufacturing know-how may provide more practical protection than old core-product patents.
• A Paragraph IV strategy is relevant only if unexpired Orange Book-listed patents remain.
• A differentiated 505(b)(2) product would need a clear clinical or usability advantage over the established three-day patch.

FAQs About Scopolamine Transdermal Systems

Is scopolamine transdermal system a biologic?

No. Scopolamine is a small-molecule anticholinergic drug. FDA approval of a competing product would use an ANDA or 505(b)(2) pathway rather than a biosimilar application.

Which adhesive is used in Transderm Scop?

The product labeling identifies polyisobutylene and light mineral oil among the inactive ingredients. The adhesive system also uses structural backing and release-liner materials [1].

Can a generic scopolamine patch use different excipients?

Potentially. An ANDA formulation must demonstrate pharmaceutical equivalence, bioequivalence, and acceptable product performance. A materially different delivery system may require a 505(b)(2) application rather than a standard ANDA.

Does heat affect scopolamine patch delivery?

External heat can alter skin permeability, adhesive behavior, and drug flux. Product labeling warns against exposing the patch to external heat sources because increased absorption can raise adverse-effect risk [1].

What is the main technical barrier to launching a scopolamine patch?

The main barrier is reproducible 72-hour delivery with reliable adhesion and controlled exposure. The formulation must remain stable, avoid crystallization, and maintain performance across manufacturing lots and storage conditions.

References

1. U.S. Food and Drug Administration. (2023). Transderm Scop: Scopolamine transdermal system prescribing information. FDA-approved labeling.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. United States Patent and Trademark Office. (2024). Patent Center and patent term adjustment records. USPTO.

4. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Patent certifications and 30-month stays. FDA.